Research Article
Catestatin as a New Prognostic Marker in Stable Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up
Table 3
Differences in plasma CST concentration (ng/ml) depending on the clinical conditions of the patients.
| | DMT2 () | No DMT2 () | | | | Median | Quartiles | Mean ± SD | Median | Quartiles | |
| | CST pre | | 16.6 | 14.59-18.29 | | 15.4 | 13.66-19.46 | 0.64 | | CSTpost | | 6.62 | 5.19-10.32 | | 7.49 | 5.03-11.98 | 0.70 | | CST δ% | | -61.51 | -64.53-31.79 | 6 | -56.6 | -64.26-43.47 | 0.49 | | AF () | | SR () | | | CST pre | | 15.21 | 13.44-17.46 | | 16.73 | 14.18-19.28 | 0.29 | | CSTpost | | 6.30 | 4.19-45.73 | | 7.64 | 5.76-10.51 | 0.33 | | CST δ% | | -62.10 | -72.09-100.02 | | -56.03 | -61.68-41.35 | 0.21 | | DCM () | | ICM () | | | CST pre | | 15.95 | 14.01-18.59 | | 16.16 | 13.14-19.28 | 0.80 | | CSTpost | | 6.89 | 4.93-10.2 | | 7.66 | 5.34-25.38 | 0.71 | | CST δ% | | -59.98 | -65.31-46.1 | 13.14-19.28 | -58.41 | -63.09-48.73 | 0.50 | | ICD () | | NO ICD () | | | CST pre | | 16.52 | 13.07-18.2 | | 15.64 | 14.25-19.22 | 0.50 | | CSTpost | | 7.8 | 5.21-105.22 | | 6.76 | 5.03-9.45 | 0.33 | | CST δ% | | -55.37 | -64.54-397.91 | | -60.25 | -63.75-51.6 | 0.20 |
|
|
DMT2: type 2 diabetes; AF: atrial fibrillation; SR: sinus rhythm; DCM: dilated cardiomyopathy; ICM: ischemic cardiomyopathy; ICD: implantable cardioverter-defibrillator.
|
